Zhou Yuan, Jiang Hong-Gang, Lu Ning, Lu Bo-Hao, Chen Zhi-Heng
Department of surgical oncology, Shanghai Jiao Tong University Affiliated First People's Hospital Jiaxing Branch, Jiaxing First Hospital, Jiaxing, Zhejiang, China E-mail :
Asian Pac J Cancer Prev. 2015;16(4):1605-8. doi: 10.7314/apjcp.2015.16.4.1605.
To investigate the expression of Ki67 protein in papillary thyroid microcarcinoma(PTMC), and to analyze its clinical significance.
Ki67 protein expression was evaluated in the tissues of 108 human PTMC and 50 other benign papillary hyperplasia of thyroid specimens using immunohistochemistry.
The expression intensity of Ki67 in PTMC and benign papillary hyperplasia of thyroid specimens were 1.45±1.83% and 0.46±0.46%.The positive expression rates were 46.3% and 14%. There were significant differences between these two groups (p<0.01). There was no significant variation of the expression intensity and positive expression rates of Ki67 in PTMC with gender, age, position of the tumor and the level of TSH pre-operation (p>0.05), but these parameters varied with tumor size, invasion by membrane and cervical lymph node metastasis (p<0.05 or p<0.01).
The expression of Ki67 in PTMC was related to tumor size, invasion by membrane and cervical lymph node metastasis, and could be the important indicator for judging clinical progress and estimating prognosis.
探讨Ki67蛋白在甲状腺微小乳头状癌(PTMC)中的表达情况,并分析其临床意义。
采用免疫组织化学方法检测108例人PTMC组织及50例甲状腺良性乳头状增生标本中Ki67蛋白的表达。
PTMC组织及甲状腺良性乳头状增生标本中Ki67的表达强度分别为1.45±1.83%和0.46±0.46%,阳性表达率分别为 46.3%和14%。两组间差异有统计学意义(p<0.01)。PTMC中Ki67的表达强度及阳性表达率在性别、年龄、肿瘤位置及术前促甲状腺激素水平方面无显著差异(p>0.05),但在肿瘤大小、包膜侵犯及颈部淋巴结转移方面存在差异(p<0.05或p<0.01)。
PTMC中Ki67的表达与肿瘤大小、包膜侵犯及颈部淋巴结转移有关,可作为判断临床进展及评估预后的重要指标。